Readoutin 104d
Bristol-Myers Squibb — Nivolumab
Phase 3 primary completion: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer.
- Date
- Mar 2027
- Type
- Readout
- Indication
- Renal Cell Carcinoma
Readoutin 104d
Phase 3 primary completion: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.